Last week, EBRP CEO, Michael Hund was invited to speak at the
@MilkenInstitute Global Conference, one of the most influential cross-sector convenings in the world, where capital, policy, science, and culture meet. Innovative global leaders across finance, health, philanthropy, government, and entertainment gather to drive global impact and action. EBRP was proud to join other innovators like Dr. Jill Biden,
@pitbull, Eva Longoria
@EvaLongoria, Tiffany Haddish
@TiffanyHaddish, Tom Brady
@TomBrady, Lionel Ritchie ,
@SHAQ, FDA Commissioner
@MartyMakary, and other world-changing global leaders.
Michael was invited to join "Rewriting the Rules: Scaling Innovation for Rare Diseases," a panel that brought together some of the most influential voices in rare disease today, or as Michael said, "The Rare Disease Avengers". Moderated by Becky Quick of CNBC, who shared her own journey as the mother of a child with SYNGAP disorder, the panel featured
@DavidFajgenbaum (Every Cure), Nicola Blackwood (
@GenomicsEngland ), Neil Kumar (
@BridgeBioPharma ), and Will Lewis (
@Insmed).
This is the kind of platform where EB Research Partnership's model belongs. Urgent patient need, breakthrough science, and catalytic capital converging to change what is possible. This week's conversation was a powerful reminder of both the scale of the challenge and the urgency of the moment. About 400 million people worldwide live with a rare disease. Only 5% have access to any approved treatment. And yet, we are at a genuine inflection point, driven by AI, genomics, platform-based therapies, and a new generation of funding models that are beginning to close the gap.
Michael shared our Venture into Cure's model, combining data platform innovation and investments in AI, collaborative research/ medical/ industry networks, and venture philanthropy deal structures that return capital to fuel the next breakthrough. An unprecedented model that has now helped accelerate three FDA approvals in two years. That model was built for exactly the kind of cross-sector stage that Milken represents. For the millions living with rare diseases that have never had a treatment, this is not incremental progress. It is a fundamental rewriting of the rules. And it is scalable.
For EBRP, being in that room is not just an honor. It is an affirmation that our approach belongs in the conversation about how the world solves rare disease. Patient-led. Capital-efficient. Scientifically rigorous. We are grateful to the Milken Institute and
@fastercures, a Center of the Milken Institute for the platform, and to every patient, family, researcher, and partner whose trust makes this work possible.
🦋 The rules are being rewritten. We intend to help continue to write them.
🎥 Watch the full panel:
milkeninstitute.org/content-…